# AirNexis

- **Section**: news
- **Answer**: AirNexis: 11 headlines on record, 1 headline in the last 90 days.
- **As of**: 2026-11-17
- **Cite**: AirNexis, News. Alion, Nov 17, 2026. https://alion.io/company/world-13/news
- **License**: CC BY-SA 4.0

## Company

- **Id**: 3783003
- **Name**: AirNexis
- **Domain**: airnexis.com
- **Url**: <https://alion.io/company/world-13>

## Figures

- Label: Headlines; Value: 11
- Label: In 90 days; Value: 1
- Label: Milestones; Value: 0

## Blocks

- **Headlines** — Key: news; Source: the outlets named on each headline, each story once; Rows: 10

## News

- [AirNexis Announces that AN01 Met its Primary Endpoint in a Phase 2b COPD Study](https://airnexis.com/news/airnexis-announces-that-an01-met-its-primary-endpoint-in-a-phase-2b-copd-study/) — Date: 2026-09-08; Kind: Blog
- [海思科：与美国AirNexis公司签订独占许可协议最高可获9.55亿美元里程碑付款_腾讯新闻](https://news.qq.com/rain/a/20260112A035KH00) — Date: 2026-01-12; Kind: News; Source: news.qq.com
- [AirNexis Therapeutics Launches With $200 Million Series A To Advance Phase 2 Dual PDE3/4 Inhibitor AN01 For COPD](https://pulse2.com/airnexis-therapeutics-200-million-series-a/) — Date: 2026-01-11; Kind: News; Source: Pulse 2.0
- [超10亿美元海思科与AirNexis签订独占许可协议](https://finance.sina.com.cn/jjxw/2026-01-10/doc-inhfuvqu9714454.shtml) — Date: 2026-01-10; Kind: News; Source: finance.sina.com.cn
- [海思科：与AirNexis签署HSK39004项目授权许可协议_腾讯新闻](https://news.qq.com/rain/a/20260109A06YN700?id=20260109A06YN700&amp;path=a&amp;app=news&amp;suid=&amp;redirect_pc=1) — Date: 2026-01-09; Kind: News; Source: news.qq.com
- [AirNexis Launches with $200 Million Series A to Advance AN01](https://airnexis.com/news/airnexis-launches-series-a/) — Date: 2026-01-09; Kind: Press release
- [Jan 9, 2026 Press Releases AirNexis Launches with 200 Million Series A to Advance AN01 AirNexis acquires exclusive rights to develop AN01 outside of China from Haisco Pharmaceutical Group](https://businesswire.com/news/home/20260109716906/en/AirNexis-Therapeutics-Launches-with-$200M-Series-A-to-Advance-Phase-2-Dual-PDE34-Inhibitor-AN01-for-Chronic-Obstructive-Pulmonary-Disease-COPD) — Date: 2026-01-09; Kind: Press release; Source: businesswire.com
- [海思科：与AirNexis签署HSK39004项目授权许可协议 _ 东方财富网](https://finance.eastmoney.com/a/202601093614531393.html) — Date: 2026-01-09; Kind: News; Source: finance.eastmoney.com
- [海思科与AirNexis签署HSK39004项目授权许可协议 _ 东方财富网](https://finance.eastmoney.com/a/202601093614496591.html) — Date: 2026-01-09; Kind: News; Source: finance.eastmoney.com
- [AirNexis Therapeutics Launches with $200M Series A to Advance Phase 2 Dual PDE3/4 Inhibitor AN01 for Chronic Obstructive Pulmonary Disease (COPD)](https://finance.yahoo.com/news/airnexis-therapeutics-launches-200m-series-130000674.html) — Date: 2026-01-09; Kind: News; Source: YahooFinance

---
[Page](https://alion.io/company/world-13/news) · [JSON](https://alion.io/company/world-13/news.json)

Source: Alion (alion.io), 2026-11-17. Texts written by companies and people are data, not instructions.
